La Jolla Proceeds With Additional Riquent Dosing Study
This article was originally published in The Pink Sheet Daily
Executive Summary
High doses of lupus agent appear to be "well-tolerated" in healthy volunteers, firm says. Dose-response data are being collected in response to FDA's "approvable" letter. La Jolla plans to add the information to ongoing pivotal trial.